ENPP3 | ApexOnco - Clinical Trials news and analysis

x

“The team is super responsive to my inquiries and suggestions”

Chief Business Officer

US public biotech company

Click here for more information

Data insights

14 April 2025

Xencor could face second challenge from former partner

J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.

Regulatory Trial results

9 September 2024

Xencor “still committed” to oncology

Subscribe to ENPP3